A citation-based method for searching scientific literature

R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
Times Cited: 2526







List of co-cited articles
742 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
81

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
725
23

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
16

Linkage of early-onset familial breast cancer to chromosome 17q21.
J M Hall, M K Lee, B Newman, J E Morrow, L A Anderson, B Huey, M C King. Science 1990
16

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
16

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
947
16

BRCA1 and BRCA2: different roles in a common pathway of genome protection.
Rohini Roy, Jarin Chun, Simon N Powell. Nat Rev Cancer 2011
663
14

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
13

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
13

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Timothy R Rebbeck, Nandita Mitra, Fei Wan, Olga M Sinilnikova, Sue Healey, Lesley McGuffog, Sylvie Mazoyer, Georgia Chenevix-Trench, Douglas F Easton, Antonis C Antoniou,[...]. JAMA 2015
226
12

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
11

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira,[...]. N Engl J Med 2014
462
10

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
517
10

Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Yu Chuan Tai, Susan Domchek, Giovanni Parmigiani, Sining Chen. J Natl Cancer Inst 2007
174
9

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
9

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
517
9

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
525
9


Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Nadine Tung, Nancy U Lin, John Kidd, Brian A Allen, Nanda Singh, Richard J Wenstrup, Anne-Renee Hartman, Eric P Winer, Judy E Garber. J Clin Oncol 2016
229
8

BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.
Haijuan Yang, Philip D Jeffrey, Julie Miller, Elspeth Kinnucan, Yutong Sun, Nicolas H Thoma, Ning Zheng, Phang-Lang Chen, Wen-Hwa Lee, Nikola P Pavletich. Science 2002
483
8

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Hanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, Marijke Wasielewski, Anja de Snoo, Rogier Oldenburg, Antoinette Hollestelle, Mark Houben, Ellen Crepin, Monique van Veghel-Plandsoen,[...]. Nat Genet 2002
761
8

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
917
8


Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
7

PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Feng Zhang, Jianglin Ma, Jiaxue Wu, Lin Ye, Hong Cai, Bing Xia, Xiaochun Yu. Curr Biol 2009
317
7

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
469
7

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
7

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
826
7

Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.
Katharina Schlacher, Nicole Christ, Nicolas Siaud, Akinori Egashira, Hong Wu, Maria Jasin. Cell 2011
655
7

Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
R Wooster, S L Neuhausen, J Mangion, Y Quirk, D Ford, N Collins, K Nguyen, S Seal, T Tran, D Averill. Science 1994
6

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
Mark E Robson, Angela R Bradbury, Banu Arun, Susan M Domchek, James M Ford, Heather L Hampel, Stephen M Lipkin, Sapna Syngal, Dana S Wollins, Noralane M Lindor. J Clin Oncol 2015
283
6

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
623
6

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Saundra S Buys, John F Sandbach, Amanda Gammon, Gayle Patel, John Kidd, Krystal L Brown, Lavania Sharma, Jennifer Saam, Johnathan Lancaster, Mary B Daly. Cancer 2017
158
6

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Fergus J Couch, Hermela Shimelis, Chunling Hu, Steven N Hart, Eric C Polley, Jie Na, Emily Hallberg, Raymond Moore, Abigail Thomas, Jenna Lilyquist,[...]. JAMA Oncol 2017
259
6

Germline BRCA1 mutations increase prostate cancer risk.
D Leongamornlert, N Mahmud, M Tymrakiewicz, E Saunders, T Dadaev, E Castro, C Goh, K Govindasami, M Guy, L O'Brien,[...]. Br J Cancer 2012
158
6

Hereditary breast and ovarian cancer: new genes in confined pathways.
Finn Cilius Nielsen, Thomas van Overeem Hansen, Claus Storgaard Sørensen. Nat Rev Cancer 2016
168
6

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
428
6

Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
472
6

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
Xin Yang, Goska Leslie, Alicja Doroszuk, Sandra Schneider, Jamie Allen, Brennan Decker, Alison M Dunning, James Redman, James Scarth, Inga Plaskocinska,[...]. J Clin Oncol 2020
65
9

Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Rohit Prakash, Yu Zhang, Weiran Feng, Maria Jasin. Cold Spring Harb Perspect Biol 2015
326
6

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
6

Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
Bing Xia, Qing Sheng, Koji Nakanishi, Akihiro Ohashi, Jianmin Wu, Nicole Christ, Xinggang Liu, Maria Jasin, Fergus J Couch, David M Livingston. Mol Cell 2006
520
6

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
748
6

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
285
6

RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis.
Natsuko Suwaki, Kerstin Klare, Madalena Tarsounas. Semin Cell Dev Biol 2011
168
6

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
Melissa S Cline, Rachel G Liao, Michael T Parsons, Benedict Paten, Faisal Alquaddoomi, Antonis Antoniou, Samantha Baxter, Larry Brody, Robert Cook-Deegan, Amy Coffin,[...]. PLoS Genet 2018
55
10

BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
D M Eccles, G Mitchell, A N A Monteiro, R Schmutzler, F J Couch, A B Spurdle, E B Gómez-García. Ann Oncol 2015
108
6


Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
6

Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2.
S K Sharan, M Morimatsu, U Albrecht, D S Lim, E Regel, C Dinh, A Sands, G Eichele, P Hasty, A Bradley. Nature 1997
831
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.